
Charles River Laboratories International, Inc. (CRL)
Trading disclosure
The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for certain activity generated through this link. Prices displayed are informational.
Learn more- Previous Close
182.34 - Open
183.70 - Bid 185.10 x 30000
- Ask 200.00 x 40000
- Day's Range
182.00 - 186.18 - 52 Week Range
144.26 - 228.88 - Volume
1,170,070 - Avg. Volume
865,026 - Market Cap (intraday)
8.911B - Beta (5Y Monthly) 1.45
- PE Ratio (TTM)
-- - EPS (TTM)
-3.71 - Earnings Date (est.) Aug 5, 2026
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
212.27
Recent News
View MorePerformance Overview
Trailing total returns as of 6/18/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Earnings Trends
View MoreAnalyst Insights
View MoreStatistics
View MoreValuation Measures
-
Market Cap
8.91B
-
Enterprise Value
11.78B
-
Trailing P/E
--
-
Forward P/E
16.61
-
PEG Ratio (5yr expected)
0.12
-
Price/Sales (ttm)
2.26
-
Price/Book (mrq)
3.03
-
Enterprise Value/Revenue
2.92
-
Enterprise Value/EBITDA
40.53
Financial Highlights
Profitability and Income Statement
-
Profit Margin
-4.59%
-
Return on Assets (ttm)
4.26%
-
Return on Equity (ttm)
-5.87%
-
Revenue (ttm)
4.03B
-
Net Income Avi to Common (ttm)
-184.65M
-
Diluted EPS (ttm)
-3.71
Balance Sheet and Cash Flow
-
Total Cash (mrq)
191.83M
-
Total Debt/Equity (mrq)
102.55%
-
Levered Free Cash Flow (ttm)
510.02M
Compare
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Company Insights
Fair Value
Dividend Score
Hiring Score
Insider Sentiment Score
Research Reports
View More-
Charles River Earnings: Near‑Term Headwinds Mask Improving Demand and Margin Outlook
Charles River Laboratories was founded in 1947 and is a leading provider of drug discovery and development services. The company’s research model & services segment is the leading provider of animal models for laboratory testing, which breeds and delivers animal research models with specific genetic characteristics for preclinical studies around the world. The discovery & safety assessment segment includes services required to take a drug through the early development process, including discovery services. The manufacturing support segment includes microbial solutions, which provides in vitro (non-animal) testing products, biologics testing services, and avian vaccine services.
RatingPrice Target -
Charles River Earnings: Near‑Term Headwinds Mask Improving Demand and Margin Outlook
Charles River Laboratories was founded in 1947 and is a leading provider of drug discovery and development services. The company’s research model & services segment is the leading provider of animal models for laboratory testing, which breeds and delivers animal research models with specific genetic characteristics for preclinical studies around the world. The discovery & safety assessment segment includes services required to take a drug through the early development process, including discovery services. The manufacturing support segment includes microbial solutions, which provides in vitro (non-animal) testing products, biologics testing services, and avian vaccine services.
RatingPrice Target -
Charles River Earnings: Near‑Term Headwinds Mask Improving Demand and Margin Outlook
Charles River Laboratories was founded in 1947 and is a leading provider of drug discovery and development services. The company’s research model & services segment is the leading provider of animal models for laboratory testing, which breeds and delivers animal research models with specific genetic characteristics for preclinical studies around the world. The discovery & safety assessment segment includes services required to take a drug through the early development process, including discovery services. The manufacturing support segment includes microbial solutions, which provides in vitro (non-animal) testing products, biologics testing services, and avian vaccine services.
RatingPrice Target -
Charles River: Downgrading Moat Rating to None and Decreasing Fair Value Estimate to $135
Charles River Laboratories was founded in 1947 and is a leading provider of drug discovery and development services. The company’s research model & services segment is the leading provider of animal models for laboratory testing, which breeds and delivers animal research models with specific genetic characteristics for preclinical studies around the world. The discovery & safety assessment segment includes services required to take a drug through the early development process, including discovery services. The manufacturing support segment includes microbial solutions, which provides in vitro (non-animal) testing products, biologics testing services, and avian vaccine services.
RatingPrice Target









